The Daily Health Drip — Wed, Oct 28, 2026

FDA Experts Resist Trump Plan to Expand Peptide Access

https://dripcast.ai/story/304225-fda-experts-resist-trump-plan-to-expand-peptide-access

HHS is allowing compounding pharmacies temporary permission to make six peptides, including BPC-157, while pursuing a formal rule change; the plan directs the FDA not to act against certain sellers. Health Secretary Robert F. Kennedy Jr. backed expanded access and said he used BPC-157 for a muscle injury, even though the peptides have not been FDA-reviewed for safety or effectiveness and the agency has warned of risks including allergic reactions, kidney damage and tumor growth. FDA scientific staff largely opposed easing restrictions and proposed safeguards such as verifying ingredients and tracking side effects, while HHS shifted to a non-enforcement approach after FDA objections.

46 US Veterans Turn to Ayahuasca on Weeklong Retreat

https://dripcast.ai/story/304083-46-us-veterans-turn-to-ayahuasca-on-weeklong-retreat

Forty-six U.S. veterans took part in a week-long ayahuasca retreat in Costa Rica, where they explored feelings they had long pushed through after years of running toward danger. Psychedelic treatments such as psilocybin could potentially benefit as many as 2.1 million veterans. A participant or source described the retreat’s value by saying, “Can’t put a price on that.”

Weekly Wall Exercise May Help Reduce Blood Pressure

https://dripcast.ai/story/304241-weekly-wall-exercise-may-help-reduce-blood-pressure

A study found that wall squats and other isometric exercises were linked to meaningful drops in resting blood pressure after four weeks, with systolic pressure falling by an average of about 9.5 points. Participants who stopped exercising saw their blood pressure return to baseline within four weeks, while those who continued once or twice a week retained a significant portion of the improvement. The study involved inactive, generally healthy adults with normal to high-normal blood pressure, so researchers say the findings may not apply to people with diagnosed hypertension or certain health limitations, and longer-term trials are needed.

Parkinson’s-like Brain Changes Reversed in Mice Over a Year

https://dripcast.ai/story/304201-parkinsons-like-brain-changes-reversed-in-mice-over-a-year

Mice given daily injections of the pesticide rotenone developed Parkinson’s-like movement problems, but gradually recovered on behavioral tests over the following year, a surprising result for researchers led by neuroscientist Xuelin Lou of the Medical College of Wisconsin. In the brain’s movement-related region, dopamine-related cell markers initially fell by about 40 percent even though overall neuron density was preserved; by 12 months, marker counts were comparable between exposed and control mice, though the signal remained weaker in exposed animals. The study, published in iScience, does not show that pesticide exposure is harmless or establish how recovery occurred, and its findings in mice should not be directly applied to people.

CDC Flags Growing Drug-resistant Germ Threat, 50,000 Deaths a Year

https://dripcast.ai/story/304198-cdc-flags-growing-drug-resistant-germ-threat-50000-deaths-a-year

The CDC has issued a new report ranking drug-resistant germs by the urgency of the threat they pose, warning that some are an urgent danger. These infections are among the country’s most pressing public health issues and kill 50,000 people each year. ABC News contributor Dr. Alok Patel discussed treatment and prevention.

Experimental Obesity Drug May Reduce Sleep Disruptions

https://dripcast.ai/story/304195-experimental-obesity-drug-may-reduce-sleep-disruptions

In two phase 3 trials, Eli Lilly’s experimental drug retatrutide reduced sleep apnea symptoms by more than half in about 68% of participants with overweight or obesity, and some participants’ apnea resolved completely. The 691 adults received weekly injections for 80 weeks, lost 12% to nearly 20% of their body weight, and also saw improvements in measures including blood pressure and cholesterol; researchers linked much of the benefit to weight loss. Retatrutide is not FDA-approved, researchers say more study is needed, and patients should not stop CPAP or other prescribed treatments.